Oracle
ORCL
NVIDIA
NVDA
Amazon
AMZN
Adobe
ADBE
Alphabet-C
GOOG
US Stock MarketDetailed Quotes
ATXS Astria Therapeutics Inc
- 7.570
- +0.070+0.93%
Close Jan 21 16:00 ET
- 7.570
- 0.0000.00%
Post 20:01 ET
427.21MMarket Cap-3.47P/E (TTM)
7.740High7.485Low235.70KVolume7.550Open7.500Pre Close1.79MTurnover0.85%Turnover RatioLossP/E (Static)56.43MShares16.90052wk High1.73P/B210.00MFloat Cap7.16052wk Low--Dividend TTM27.74MShs Float1017.600Historical High--Div YieldTTM3.40%Amplitude2.360Historical Low7.599Avg Price1Lot Size
About Astria Therapeutics Inc Company
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
Company Profile
SymbolATXS
Company NameAstria Therapeutics Inc
Listing DateJun 25, 2015
Issue Price12.00
Founded2008
CEODr. Jill C. Milne, PhD
MarketNASDAQ
Employees59
Fiscal Year Ends12-31
Address22 Boston Wharf Road,10th floor
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02210
Phone1-617-349-1971
Websitehttp://www.astriatx.com
Company Executives
- Name
- Position
- Salary
- Dr. Jill C. Milne, PhD
- Director, President and Chief Executive Officer
- 2.96M
- Dr. Christopher Morabito, M.D.
- Chief Medical Officer
- 1.32M
- Andrea Matthews
- Chief Business Officer
- --
- Noah Clauser
- Chief Financial Officer, Principal Accounting Officer and Treasurer
- 1.35M
- Andrew Komjathy
- Chief Commercial Officer
- --
- Benjamin Harshbarger
- Chief Legal Officer
- --
- Kenneth M. Bate
- Chairman of the Board
- 194.17K
- Dr. Sunil Agarwal, M.D.
- Director
- --
- Dr. Jonathan Violin, M.B.A.,PhD
- Independent Director
- 158.67K
- Dr. Joanne T. Beck, PhD
- Independent Director
- 256.17K
- Michael D. Kishbauch
- Independent Director
- 157.67K
- Frederick C. Callori
- Independent Director
- 152.67K
- Hugh M. Cole
- Independent Director
- 151.17K
- Gregg Anthony Lapointe, C.P.A.,M.B.A.
- Independent Director
- 163.67K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.